Risankizumab治疗儿童银屑病的III期OptIMMize-1研究疗效与安全性
OptIMMize-1是一项III期多中心研究,纳入137例中重度儿童银屑病患者。第16周时,risankizumab组sPGA0/1达79.6%、PASI75达85.2%、PASI90达64.8%、PASI100达40.7%;第52周疗效维持或改善,安全性与成人研究一致。
要点
- Risankizumab在儿童中重度银屑病第16周显示高皮损清除率,PASI100优于乌司奴单抗。
- 第52周疗效维持或改善,瘙痒和生活质量持续改善。
- 安全性特征与既往成人银屑病研究一致。
核心结论
- Risankizumab在儿童中重度银屑病患者中耐受良好,第16周显著改善皮损清除、瘙痒和生活质量,第52周疗效维持或改善。
研究设计与样本
- OptIMMize-1(NCT04435600)为III期、多中心、四部分研究,共纳入137例儿童中重度银屑病患者。
- 第2部分A期16周随机(risankizumab:ustekinumab=2:1),B期最长36周随机治疗或撤药,C期潜在16周再治疗;第1、3、4部分为52周开放标签研究。
主要发现
- 第2部分第16周,risankizumab组(n=54)sPGA0/1为79.6%、sPGA0/1+≥2GI为68.5%、PASI75为85.2%、PASI90为64.8%、PASI100为40.7%。
- 第2部分第16周,ustekinumab组(n=28)sPGA0/1为75.0%、sPGA0/1+≥2GI为67.9%、PASI75为85.7%、PASI90为60.7%、PASI100为17.9%。
- 第4部分(n=30)第16周sPGA0/1为90.0%、sPGA0/1+≥2GI为83.3%、PASI75为86.7%、PASI90为76.7%、PASI100为43.3%,第52周维持或改善。
- 第1和3部分皮损清除结局与第2和4部分持续risankizumab治疗一致。
- 第16周和52周观察到瘙痒和生活质量改善(仅第2部分评估),安全性特征与既往成人研究一致。
临床怎么用
- Risankizumab可作为儿童中重度银屑病的治疗选择,第16周起效显著且第52周疗效维持。
- 治疗中需关注瘙痒和生活质量改善,安全性特征与成人一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for paediatric patients with psoriasis are limited, and additional, more advanced therapies are needed. Risankizumab is an interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis in adults. OBJECTIVES: To evaluate efficacy and safety of risankizumab through 52 weeks in paediatric patients with moderate-to-severe psoriasis. METHODS: OptIMMize-1 (NCT04435600) was a phase III, multicentre, 4-part study. Parts 1, 3, and 4 were 52-week, open-label studies. Part 2 consisted of a 16-week initial treatment period (Period A; 2:1 risankizumab:ustekinumab randomization), followed by an up to 36-week randomized treatment or withdrawal period (Period B) for risankizumab responders, with a potential 16-week retreatment period (Period C) for patients who experience a disease flare. Risankizumab nonresponders and patients randomized to ustekinumab in Period A received risankizumab during Period B. Key outcomes included the proportion of patients achieving a static Physician's Global Assessment (sPGA) score of clear/almost clear (sPGA0/1), sPGA0/1 with ≥2-grade improvement (sPGA0/1+≥2GI), or ≥75%/≥90%/100% improvement in PASI (PASI75/90/100). The study also assessed itch severity, quality of life, and safety. RESULTS: A total of 137 patients enrolled. In Part 2 (risankizumab, n = 54; ustekinumab, n = 28), week 16 response rates were similar: sPGA0/1 was 79.6% for risankizumab and 75.0% for ustekinumab; sPGA0/1+≥2 GI rates were 68.5% vs. 67.9%; PASI75 rates were 85.2% vs. 85.7%; and PASI90 rates were 64.8% vs. 60.7%. PASI100 responses were higher with risankizumab (40.7%) than with ustekinumab (17.9%). In Part 4 (n = 30), week 16 rates were sPGA0/1: 90.0%, sPGA0/1+≥2GI: 83.3%, PASI75: 86.7%, PASI90: 76.7%, and PASI100: 43.3%; week 52 responses were maintained or improved. Skin clearance outcomes in Parts 1 and 3 were consistent with those observed with continuous risankizumab treatment in Parts 2 and 4. Improvements in itch and quality of life (assessed in Part 2 only) were observed at weeks 16 and 52. Risankizumab safety profiles were consistent with those observed in prior adult psoriasis studies. CONCLUSIONS: Risankizumab was well tolerated in paediatric patients, resulting in marked improvements in skin clearance, itching, and quality of life after 16 weeks of treatment. Efficacy was maintained or improved at week 52, supporting risankizumab use for moderate-to-severe psoriasis in this population.
引用
- Magnolo N, Lara WL, Reich A, et al. Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study. Br J Dermatol. 2026. PMID: 42791206. doi:10.1093/bjd/ljag403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。